Seeking Alpha - Healthcare CorMedix announces new commercial agreement...\n more…
Globe Newswire BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and...\n more…
Zacks Investment Research Shares of CorMedix (CRMD) have been struggling lately and have lost 7.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock...\n more…
Zacks Investment Research Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell...\n more…
Zacks Investment Research CorMedix (CRMD) closed the last trading session at $5.74, gaining 45.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street...\n more…